Linked Life Data

10849941

Source:http://linkedlifedata.com/resource/pubmed/id/10849941

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2000-7-14
pubmed:abstractText
Despite the availability of various lipid lowering drugs, the treatment of hyperlipidemia, one of the most important risk factors for morbidity and mortality after organ transplantation, remains a therapeutic challenge. We investigated the safety and efficacy of a new HMG-CoA reductase inhibitor, atorvastatin, in renal transplant patients whose serum lipids were insufficiently controlled by diet and treatment with other lipid lowering drugs. Twenty-four patients (14 males/10 females; mean age 51.2 +/- 2.3 years) were converted to low dose atorvastatin (10 mg/day) at a mean of 67.7 +/- 8.6 months after renal transplantation and prospectively followed for 3 months after initiation of the study drug. HDL, LDL, and total cholesterol, triglycerides, serum creatinine and CPK levels were evaluated pre (-3, -1, 0 months) and post conversion (+1, +3 months). In the eighteen patients who completed the study, low dose atorvastatin therapy led to a significant reduction in total cholesterol (304.6 +/- 13.2 vs. 247.6 +/- 12.0 mg/dl; p = 0.007) and LDL cholesterol (191.9 +/- 9.0 vs. 141.8 +/- 14.7 mg/dl; p < 0.0001) and a modest reduction in serum triglyceride levels at three months after conversion. We conclude that low dose atorvastatin (10 mg/day) can be successfully used and appears to be safe in the treatment of posttransplant hyperlipidemia. Its long-term effects on patient morbidity and mortality as well as graft survival should be investigated in larger and more prolonged prospective trials.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0043-5325
pubmed:author
pubmed:issnType
Print
pubmed:day
21
pubmed:volume
112
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
358-61
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10849941-Adult, pubmed-meshheading:10849941-Aged, pubmed-meshheading:10849941-Anticholesteremic Agents, pubmed-meshheading:10849941-Cholesterol, HDL, pubmed-meshheading:10849941-Cholesterol, LDL, pubmed-meshheading:10849941-Cross-Over Studies, pubmed-meshheading:10849941-Cyclosporine, pubmed-meshheading:10849941-Dose-Response Relationship, Drug, pubmed-meshheading:10849941-Female, pubmed-meshheading:10849941-Heptanoic Acids, pubmed-meshheading:10849941-Humans, pubmed-meshheading:10849941-Hydroxymethylglutaryl-CoA Reductase Inhibitors, pubmed-meshheading:10849941-Hyperlipidemias, pubmed-meshheading:10849941-Kidney Failure, Chronic, pubmed-meshheading:10849941-Kidney Function Tests, pubmed-meshheading:10849941-Kidney Transplantation, pubmed-meshheading:10849941-Liver Function Tests, pubmed-meshheading:10849941-Male, pubmed-meshheading:10849941-Middle Aged, pubmed-meshheading:10849941-Pyrroles, pubmed-meshheading:10849941-Treatment Outcome, pubmed-meshheading:10849941-Triglycerides
pubmed:year
2000
pubmed:articleTitle
Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
pubmed:affiliation
Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin III, Allgemeines Krankenhaus der Stadt Wien, Vienna, Austria.
pubmed:publicationType
Journal Article, Clinical Trial